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on sleep dysfunction in Parkinson’s disease
Weidong Pan1,2, Shin Kwak2, Guoyan Li3, Yiyun Chen1 and Dingfang Cai4*Abstract
Background: This study aimed to evaluate the effects of add-on Yang-Xue-Qing-Nao granules (YXQN) on sleep
dysfunction in patients with Parkinson’s disease (PD).
Methods: PD participants fitted with an actigraph took either YXQN or placebo granules in a randomized manner
for 12 weeks while maintaining other anti-parkinsonism medications (e.g., dopaminergic agent, dopamine agonist)
unchanged. Additional participants without sleep disturbance or PD served as controls. The changes in detrended
fluctuation analysis (DFA) of physical activity with respect to diurnal activity (DA), evening activity (EA), nocturnal
activity (NA), Parkinson’s disease sleep scale (PDSS) score and unified Parkinson’s disease rating scale (UPDRS) score
were evaluated every 4 weeks during the 12-week YXQN intervention period and again at week 16.
Results: A total of 61 (placebo group, n = 30; YXQN group, n = 31) idiopathic PD participants with sleep dysfunction
(mean age ± standard deviation, 63.4 ± 8.6 years; mean duration of illness, 5.8 ± 6.6 years) completed the study.
Significant improvements in EA (p = 0.033, 0.037 and 0.029), DA (p = 0.041, 0.038 and 0.027) and PDSS score
(p = 0.034, 0.028 and 0.029) were observed in the YXQN group at weeks 8 and 12, and maintained until week 16,
respectively.
Conclusion: YXQN improved the DFA parameters, and PDSS and UPDRS scores in PD participants.Introduction
A high incidence of sleep dysfunction has been reported
in patients with Parkinson’s disease (PD) [1-3], especially
in patients receiving dopaminergic agent treatment [3,4].
PD patients with significant sleep dysfunction may indicate
early progressive degeneration of the sleep centers [5].
Chinese medicine (CM) preparations have shown benefi-
cial effects on aging-related symptoms [6,7] and chronic
diseases, such as PD [8-13], including improved nocturnal
sleep disorder in PD patients [14].
As a CM compound for treating headache and dizziness
associated with serious sleep disturbances, Yang-Xue-Qin-
Nao granules (YXQN) attenuate cerebral microcirculatory
disturbances during ischemia-reperfusion injury in vivo
[15], which might improve the sleep dysfunction in PD
patients. YXQN (Tianjin Tasly Pharmaceutical Co. Ltd.,
Tianjin, China) is a newly developed compound medicine
that was approved in 1996 by the China State Food and* Correspondence: dingfangcai@gmail.com
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reproduction in any medium, provided the orDrug Administration for the treatment of headache and
dizziness associated with cerebrovascular diseases. The
granules are composed of 11 herbs: Radix angelicae sinensis
(Dang Gui), 6.76%; Rhizoma chuanxiong (Chuan Xiong),
6.76%; Radix paeoniae alba (bai shao), 5.41%; Ramulus
uncariae cum uncis (Gou Teng), 13.51%; Caulis spatholobi
(Ji Xue Teng), 13.51%; Spica prunellae (Xia Ku Cao),
13.51%; Concha margaritifera usta (Zhen Zhu Mu), 13.51%;
Radix rehmanniae preparata (Di Huang), 5.41%; Semen
cassiae (Jue Ming Zi), 13.51%; Rhizoma corydalis yanhusuo
(Yan Hu Suo), 6.76%; and Herba asari (Xi Xin), 1.35%.
Available evidence from in vitro studies has revealed that at
least six chemicals derived from these herbs exhibit antioxi-
dant potential, inhibit neutrophil adhesion to endothelial
cells and decrease infarct size and brain tissue damage [15].
YXQN was reported to show effects on functional and
structural changes in microvessels in the cerebral cortex of
gerbils induced by ischemia-reperfusion injury [15]. These
granules might improve non-motor symptoms, such as
dizziness, headache and even depression [16,17].
This study aimed to evaluate the effects of add-on YXQN
in PD patients by analyzing actigraphic measurements. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(DFA) parameters were analyzed by the actigraph records
for diurnal activity (DA), evening activity (EA) and noctur-
nal activity (NA).
Methods
Participant inclusion and exclusion criteria
The UK Parkinson’s Disease Society Brain Bank clinical
diagnostic criteria were used to assess the eligibility for
participation in this study. PD was defined by the presence
of at least two of the four cardinal features (bradykinesia,
tremor, rigidity and postural reflex abnormality). Subjects
were included if they had idiopathic PD, were being
treated with daytime levodopa and had at least three
awakenings per night occurring at least three nights per
week and attributable to PD symptoms [20]. Exclusion
criteria were current direct dopamine agonist treatment,
dementia, depression, psychosis, hallucinations, and prior
intolerance to dopamine agonists or use of sleep medica-
tions. All patients were at least 40 years of age, were evalu-
ated in the middle of their levodopa dose cycle at maximal
mobility (‘on’) for the severity of parkinsonism and signed
informed consent before participation. The study was
approved by The Ethics Committee of Shuguang Hospital
Affiliated to Shanghai University of Traditional Chinese
Medicine, and was performed in accordance with the
principles outlined in the Declaration of Helsinki.
Randomization, masking and drug administration
An unmasked pharmacist generated randomization
codes using an Excel (Microsoft Office) random num-
ber generator (Microsoft, USA) in blocks of two and
four participants. Kits were given sequential numbers
that corresponded to the randomization key and were
maintained in a secure location. When randomized,
each successive participant was assigned by an electronic
Clinical Trial Management System to the next numbered
kit in sequence at each site. YXQN and the placebo gran-
ules (one-tenth active compound of YXQN with a flavor
enhancer) were manufactured by the same pharmaceutical
company (Tianjin Tasly Pharmaceutical Co. Ltd., China),
and the shape and color of both types of granules were
identical (non-distinguishable by the participants). Tablets
containing YXQN (4 g) or placebo granules (4 g) were
packaged into kits of several blister packs (1 week of treat-
ment per pack). All participants and study personnel were
blinded to the treatment assignment. The PD participants
were randomized into either a YXQN group or a placebo
group, and were required to take the granules three times
per day for 12 consecutive weeks. Anti-parkinsonian drug
administration was not changed throughout the study
(Table 1). The participants were not treated by any other
complementary and alternative treatments, such as other
CM, Tai Chi exercise or acupuncture. The control groupconsisted of participants with one or more conditions
such as idiopathic hypertension, chronic nephritis, chronic
inflammatory demyelinating polyneuropathy and coronary
heart disease, but no sleep disturbance or PD, who were
diagnosed by physicians and neurologists. The control par-
ticipants were invited to participate in a 1-week consecutive
recording session to evaluate their sleep characteristics.
Their activities and DFA parameters were recorded for
comparison, because we found that the scores of the
healthy controls changed only very slightly after 1 year
(Weidong Pan, unpublished observation).
Equipment and data analysis
Each participant wore an actigraph which was a small
watch-type activity monitor equipped with a computer
(MicroMini-Motionlogger; Ambulatory Monitoring Inc.,
USA), on the wrist of their non-dominant hand for 6 con-
secutive days in the series time windows (4 weeks each)
during the 16-week observation period. Zero-crossing
counts were recorded every minute by the actigraph to
quantify the level of physical activity. The data were trans-
mitted to a computer and the activity scores were plotted
for 3 consecutive days to determine the daily profiles and
biological rhythms of each participant. The data acquired
from the actigraph were categorized into DA (between
6 a.m. and 6 p.m.), EA (between 6 p.m. and 9 p.m.) and
NA (between 9 p.m. and 6 a.m.). Discontinuous data were
combined through an integrative method as follows. We di-
vided the difference between the two connecting terminals
of the two data into four quarters, made the connection
into an oblique line (it was a broken line before integration)
to avoid connecting errors, and connected all the pieces of
data into one continuous sequence for fluctuation analysis
[18]. Subsequently, we analyzed the DFA value α to evaluate
the relationships between time scales and magnitudes of
fluctuation (standard deviations: SDs) within each time
scale [21,22]. More correlated signals represented a greater
growth of the fluctuation magnitude with increasing
time scale or length of data windows [18]. The outcome
measures were assessed at baseline and every 4 weeks
during the 16-week intervention.
Clinical evaluation
The unified Parkinson’s disease rating scale (UPDRS) score
[23] and Parkinson's disease sleep scale (PDSS) score [24]
were evaluated for all participants at week 0 (baseline) and
at weeks 4, 8, 12 and 16 by neurologists who were blinded
to the test granules. The PDSS score in the control group
was evaluated once on the first day of the recording week.
Statistical analysis
Repeated-measure ANOVAs were conducted to test the
differences among changes in outcomes at baseline and
every 4 weeks for 16 weeks. When a significant difference
Table 1 Subject characteristics
Subjects Control group (n = 35) Placebo group (n = 30) YXQN group (n = 31) P value
Age (yr) 66.8 ± 7.7 67.1 ± 10.2 68.6 ± 9.2 0.89
Men/Women 21/14 19/11 18/13 -
Disease duration - 6.1 ± 4.9 5.9 ± 4.7 0.17
UPDRS score - 37.59 ± 10.51 38.35 ± 6.78 0.23
Levodopa/DCI (mg/day) - 412.5 ± 162.8 421.3 ± 142.9 0.65
Pramipexole(mg/day) - 1.11 ± 0.39 1.03 ± 0.78 0.08
Entacapone (mg/day) - 198.28 ± 88.47 203.67 ± 78.38 0.12
Selegiline hydrochloride (mg/day) - 8.33 ± 6.94 8.21 ± 3.76 0.26
Adamantatamine (mg/day) - 118.73 ± 96.59 116.31 ± 89.6 0.19
Artane hydrochloride (mg/day) - 4.82 ± 2.91 4.65 ± 2.36 0.08
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conducted between the YXQN group and the placebo
group to compare the UPDRS total scores, the α values
of DA, EA and NA, and the changes in the PDSS scores.
The differences at baseline between the control group
and the YXQN group, and between the control group
and the placebo group were analyzed by t-tests. A signifi-
cant difference was defined as P < 0.05. SPSS for Windows
version 17.0 (SPSS China, China) was used for statistical
analyses. All data were expressed as the mean ± SD.
Results
Eighty-two idiopathic PD patients at the Department of
Neurology of Shuguang Hospital Affiliated to Shanghai
University of Traditional Chinese Medicine were recruited,
and 70 patients who met the criteria were enrolled. Five PD
participants in the YXQN group withdrew from the study
for drug-related reasons: two participants experienced nau-
sea and three were unable to tolerate the bitter taste of
YXQN. Four participants in the placebo group dropped
out: one participant was unable to tolerate the bitter taste
of placebo, two participants dropped out because of ineffi-
cacy and one dropped out through a conflict with other
CM preparations prescribed for concomitant diseases.
A total of 61 PD participants completed the trial, and
were randomized into the YXQN group (n = 31) and the
placebo group (n = 30) (Table 1). All control participants
(n = 35) completed 1 week of recording. No differences
in age or sex distribution were observed among the three
groups. No differences in PD duration, UPDRS total score,
PDSS score, α values of DFA for DA, EA and NA or dose
of levodopa at baseline were observed between the YXQN
group and the placebo group (Table 1).
NA was decreased after the additional treatment in
the YXQN group (Figure 1B and C). The improvements
in NA in the YXQN group after continuous daily treat-
ment for 12 weeks were similar to those in the control
group (Figure 1A and C). In both the YXQN group and
the placebo group, the α values of DFA for DA, EA andNA, and the PDSS score at baseline were significantly
different from those in the control group (Figure 2). The
α values of DA in the YXQN group decreased slightly
during the 16-week observation period (Figure 2A). The
α values for EA in the YXQN group were decreased at
weeks 4, 12 and 16 compared with the placebo group
(Figure 2B). Compared with the placebo group, the
YXQN group had significantly increased α values for
NA at weeks 8, 12 and 16, and increased PDSS values
(Figure 2C and D). The better UPDRS scores were ob-
served in the YXQN group at the end of the intervention
compared with the placebo group, but there were no sig-
nificant changes compared with baseline in either group
of PD participants (Table 2). The improvements in the α
values and PDSS score in the YXQN group were similar
to those in the control group, and the effects in the YXQN
group were maintained for 4 weeks (Figure 2). No serious
adverse events were observed.
Discussion
Herbal treatments may influence PD symptoms and the
effectiveness of dopaminergic therapy [25]. The improved
NA associated with YXQN, but not with nocturnal
levodopa, may be attributed to differences in the
pharmacologic actions on dopamine receptor subtypes
or the effects of YXQN on other neurotransmitter systems
[15]. The UPDRS scores improved slightly after YXQN
administration (Table 2), and the observed benefits might
be caused by the sleep effects, rather than direct motor
effects, in patients with PD.
Currently, complementary and alternative treatments
are becoming more effective for the treatment of chronic
disorders, such as dementia, sleep disorder, mood disorders,
high blood pressure and anxiety [26-31]. However, there is
no reliable quantitative and objective equipment to evaluate
the effects. Several studies have demonstrated the utility of
actigraphs [14,18-20] and their application in PD to assess
disease severity, NA and circadian rest-activity rhythm with
aging and Alzheimer’s disease [32], and to distinguish
Figure 1 Daily profiles of actigraph counts showing the biological rhythm before and after granule ingestion in the control group (A),
placebo group (B), and Yang-Xue Qing-Nao granule (YXQN) group (C). The light green color indicates sleep duration.
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actigraphs cannot distinguish between NA owing to wake-
fulness and NA caused by other nocturnal sleep distur-
bances, such as REM sleep behavior disorder, periodic limb
movements or sleep apnea, none of the latter effects are
caused or worsened by dopamine treatment. Nocturnal
sleep disturbance may arise from these symptoms [2-4],
and demonstration of improvements may indicate that the
sleep disturbance can be treated by alternative therapies
such as YXQN. The exact mechanisms of the effects of
YXQN on REM sleep behavior disorder, periodic limb
movements or sleep apnea remain to be determined.In this study, administration of YXQN three times per
day for 12 weeks was effective for improving EA and
sleep dysfunction in PD participants, and these improve-
ments were maintained for 16 weeks. A lower α value of
DFA indicates a higher activity ability during the diurnal
period, while a higher α value of DFA reflects a lower
activity ability during the nocturnal period [18,21,22]. No
treatment-related adverse events, such as hypotension,
abnormal liver and/or renal function, diarrhea or coagu-
lation defects, were observed in the study participants,
indicating that YXQN is likely to be a safe therapy for
PD patients with sleep dysfunction.
Figure 2 Mean changes in α values of detrended fluctuation analysis (DFA) in diurnal activity (DA) value (A), evening activity (EA) value (B),
diurnal activity (DA) value (C) and Parkinson’s disease sleep scale (PDSS) score (D) at baseline, and at weeks 4, 8, 12 and 16. Black circles
indicate the Yang-Xue Qing-Nao granule (YXQN) group, white circles indicate the placebo group and white squares indicate the control group. *P < 0.05,
vs. baseline; ☆P < 0.05, vs. placebo group; #P < 0.05, ##P < 0.01, vs. YXQN group or placebo group.
Table 2 Changes in detrended fluctuation analysis (DFA) values, Parkinson’s disease sleep scale (PDSS) and unified
Parkinson’s disease rating scale (UPDRS)
Variable
Mean changes from baseline (95%CI) Between group difference (96%CI)
YXQN Placebo YXQN vs Placebo P value
α value of DA
Week 8 −0.9 [−1.1 to −0.7] −0.2 [−0.3 to 0.1] −0.7 [−1.0 to −0.8] 0.056
Week 12 −1.0 [−1.2 to −0.7] −0.1 [−0.3 to 0.2] −0.8 [−1.1 to −0.7] 0.051
Week 16 −0.9 [−1.1 to −0.6] −0.2 [−0.2 to 0.3] −0.9 [−1.1 to −0.7] 0.072
α value of EA
Week 8 −1.1 [−1.4 to −0.6] −0.1 [−0.1 to 0.2] −1.0 [−1.3 to −0.5] 0.048
Week 12 −0.9 [−1.0 to −0.6]* 0.1 [−0.3 to 0.4] −1.1 [−1.6 to −0.7] 0.036
Week 16 −0.9 [−1.1 to −0.7]* −0.2 [−0.4 to 0.3] −0.9 [−1.3 to −0.8] 0.041
α value of NA
Week 8 1.0 [0.8 to 1.6]* −0.3 [−0.6 to 0.4] 1.1 [0.7 to 1.5] 0.017
Week 12 1.1 [0.7 to 1.5]* −0.1 [−0.5 to 0.5] 1.0 [0.6 to 1.4] 0.038
Week 16 0.9 [0.6 to 1.7]* −0.2 [−0.5 to 0.4] 0.9 [0.7 to 1.6] 0.042
PDSS score
Week 8 12.1 [7.6 to 13.7]* 2.9 [−4.1 to 9.7] 10.7 [6.9 to 16.5] 0.026
Week 12 11.9 [7.1 to 14.2]* 3.3 [−6.6 to 7.3] 9.8 [8.7 to 15.9] 0.029
Week 16 9.8 [7.0 to 14.6]* 3.2 [−4.9 to 5.1] 9.9 [7.4 to 17.6] 0.048
UPDRS score
Week 8 −6.6 [−11.4 to −2.8] −1.7 [−2.8 to 3.9] −4.9 [−6.7 to −2.7] 0.076
Week 12 −5.7 [−10.8 to −1.9] −0.9 [−1.7 to 2.1] −5.1 [−8.3 to −2.4] 0.069
Week 16 −5.2 [−8.9 to −2.1] 2.1 [−4.2 to 6.1] −4.6 [−7.5 to −3.1] 0.153
*: P < 0.05, compared with baseline.
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YXQN improved the DFA parameters, and PDSS and
UPDRS scores in PD participants.
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